Loading...
Profile
Frank M. Torti, M.D.

Frank M. Torti, M.D.

Charles L. Spurr Professor, Internal Medicine-Hematology and Oncology
Chair, Cancer Biology
Professor, Internal Medicine-Hematology and Oncology
Comprehensive Cancer Center
Contact Information
Appointment:
336-713-5440
Office:
336-716-4464
Fax:
336-716-5687
Clinical Specialties
Genitourinary Oncology
Education & Training
  BAJohns Hopkins University1969
  MAJohns Hopkins University1969
  MPHHarvard School of Public Health1973
  MDHarvard Medical School1974
ResidencyMedicineBeth Israel Deaconess Med Ctr1976
InternshipMedicineBeth Israel Deaconess Med Ctr1975
Memberships
American Urological Association
International Bioiron Society
American Association of Advancement of Science
American Coll of Physicians
American Society of Hematology
Int'L Society of Interferon Research
Society for Free Radical Biology and Medicine
American Federation of Clinical Research
North Carolina Medical Society
American Society of Cell Biology
American Society of Clinical Oncology
American Medical Association
American Association of Cancer Research
NPI Number
1134180698
Frank M. Torti, M.D.

Frank M. Torti, M.D.

Charles L. Spurr Professor, Internal Medicine-Hematology and Oncology
Chair, Cancer Biology
Professor, Internal Medicine-Hematology and Oncology
Comprehensive Cancer Center
Contact Information
Appointment:
336-713-5440
Office:
336-716-4464
Fax:
336-716-5687
Research Interests
basic mechanisms, education/training (all f, t,, educational service, immunology/allergy/inflammatio, respiratory system, facility construction/infrastr, biological/chemical compounds, cancer/oncogenesis, clinical trials, health services/training, information sciences, technology /technique developm
Recent Publications
Prostate cancer risk associated loci in African Americans, Cancer Epidemiol Biomarkers Prev, 09/11/2009

Ferritin for the clinician, Blood Rev, 06/03/2009

Phase I trial of angiotensin-(1-7): an endogenous anti-angiogenic hormone [abstract], J Clin Oncol, 05/28/2009

A general map of iron metabolism and tissue-specific subnetworks, Mol Biosyst, 05/28/2009

Regulatory effects of ferritin on angiogenesis, Proc Natl Acad Sci U S A, 04/20/2009

Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator, Blood, 03/20/2009

Ph.D. training in cancer biology, Cancer Res, 02/12/2009

Health system correlates of receipt of radiation therapy after breast-conserving surgery: a study of low-income Medicaid-enrolled women, Am J Manag Care, 01/28/2009

Post-transcriptional modulation of iron homeostasis during P53-dependent growth arrest, J Biol Chem, 01/06/2009

Non-invasive imaging for determination of global tissue characteristics [patent], Wake Forest University Health Sciences, assignee; US patent 7,333,845; 2008 Feb 19;, 08/27/2008

Curcumin: from ancient medicine to current clinical trials, Cell Mol Life Sci, 07/31/2008

Bi-directional translational research with angiotensin-(1-7) uncovers placental growth factor as a therapeutic target [abstract], In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research ; 2008 Apr 12-16; San Diego (CA). Philadelphia (PA): AACR, 07/31/2008

Testicular cancer, Abeloff's clinical oncology. 4th ed, 07/15/2008

The transfusion iron overload score is a potential predictor of survival in stem cell transplant patients [abstract], Blood, 04/28/2008

Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin, Am J Physiol Lung Cell Mol Physiol, 04/17/2008

A phase II pilot study of safety and effects on bone resorption of AZD0530 in prostate or breast cancer patients with bone metastases [abstract], J Bone Min Res, 03/31/2008

Influence of ligand structure on Fe(II) spin-state and redox rate in cytotoxic tripodal chelators, J Inorg Biochem, 03/28/2008

A phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma, Cancer Chemother Pharmacol, 02/22/2008

Thermal ablation therapeutics based on CN(x) multi-walled nanotubes, Int J Nanomedicine, 02/22/2008

A human bone morphogenetic protein antagonist is down-regulated in renal cancer, Mol Biol Cell, 02/19/2008

Excess capacity of the iron regulatory protein system, J Biol Chem, 10/10/2007

Extensive excess capacity of the IRP system in cellular iron regulation [abstract], Am J Hematol, 08/14/2007

Ferritin inhibits cleavage of high molecular weight kininogen by elastase and mast cell tryptase [abstract], Am J Hematol, 08/14/2007

Curcumin, a cancer chemopreventive agent, is a biologically relevant iron chelator [abstract], Am J Hematol, 08/09/2007

Ferritin-mediated iron transport via TIM-2 in mouse kidney cells [abstract], Am J Hematol, 08/09/2007

Structural requirements for the endocytosis of H-ferritin by murine TIM-2 [abstract], Am J Hematol, 08/09/2007

The carcinogen azonymethane causes necrosis and oxidative stress in rat liver within 48 hours after injection, a toxic effect that is however strongly mitigated by pretreatment with the coffee components kahweol and cafestol [abstract], Naunyn Schmiedebergs Arch Pharmacol, 07/18/2007

Bone metastases in prostate cancer: a targeted approach, Curr Opin Oncol, 07/10/2007

Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer, Cancer, 10/30/2006
All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

Loading...

Quick Reference

Important Numbers
Media Inquiries 
336-716-4587
Patient Information 
336-713-0000
To Arrange Satellite Interviews 
336-716-4434

Find a Doctor

e.g., "allergy," "diabetes"

Loading...

Disclaimer: The information on this Web site is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.